Nick Szubiak, MSW, LCSW Director, Clinical Excellence in Addictions

Slides:



Advertisements
Similar presentations
Mady Chalk, PhD., MSW Treatment Research Institute November, 2013.
Advertisements

13 Principles of Effective Addictions Treatment
Single State Agency responsible for planning, coordination and regulation of the statewide network of prevention, intervention, treatment and recovery.
Principles of Drug Addiction Treatment: What Works with Offenders? Rita Dries July 2006.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Integrated Health Home Services in an Opioid Treatment Program: A Model Yngvild Olsen, MD, MPH Institutes for Behavior Resources, Inc./REACH Health Services.
Attractive Addiction Treatment...? Can we make addiction treatment engaging?
STEP VA: System Transformation, Excellence and Performance in Virginia Virginia’s pathway to excellence in behavioral healthcare and to a healthy Virginia.
Responding to Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
The National Prevention Strategy and Behavioral Health Care: Prevention Is Now RADM Peter J. Delany, Ph.D., LCSW-C Substance Abuse and Mental Health Services.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
Co-occurring Challenges: Leveraging ADAP and ACA to Address Hepatitis C and Substance Use Disorders Daniel Raymond Policy Director Harm Reduction Coalition.
Opioid addiction treatment: Challenges (and opportunities) for community practice Marc Fishman MD.
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
Building a Common Vision for Recovery in America Michael T. Flaherty, Ph.D. Pittsburgh, Pennsylvania White House Compassion in Action Roundtable September.
An integrated approach to addressing opiate abuse in Maine Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
Recovery Support Services and Client Outcomes: Results of Two Interim Evaluations in Texas College on Problems of Drug College on Problems of Drug Dependence.
November 4, Substance Use Disorders Consultation Service (SUDS): Integrating Addiction Services in an Acute Medical Setting Anika Alvanzo, MD, MS.
Health Reform: Local Safety Net Implications Karen J. Minyard, Ph.D., Executive Director, Georgia Health Policy Center, Georgia State University.
1 December 8, 2015 Crista M. Taylor, LCSW-C Director, Information, Planning and Development Adrienne Breidenstine, MSW Director of Opioid Overdose Prevention.
Integrating Substance Use Treatment into Primary Care: You can do it! Aaron Fox, MD, MS, Assistant Professor of Medicine Albert Einstein College of Medicine/Montefiore.
Understanding Drug Abuse and Addiction: What Science Says Developed by the National Institute on Drug Abuse (NIDA) National Institutes of Health Bethesda,
FAMILY RECOVERY NETWORK EVENT: What is Substance Abuse Treatment? Patrick Seche, MS, CASAC Strong Recovery Addiction Psychiatry Division Department of.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
Medical Assisted Treatment
Medication Assisted Treatment
Thomas F. Babor, Ph.D., MPH Dennis McCarty, Ph.D.
Addressing Mental Health and Substance Use Disorders in Veterans
Module 4: Engaging KPs with HIV and SRH Services
Illinois’ 1115 Behavioral Health Transformation Waiver
Entry into care Failure to initiate timely HIV care after diagnosis is common ~75% of newly diagnosed link to care within 6-12 months Delayed entry into.
Drugs and Neuron Communication
Integrating Care Through Partnerships – Missouri’s Experience
COLLECTIVE IMPACT APPROACH TO ADDRESSING
Health Reform, HITECH and Workforce
Public Substance Use Disorder Treatment for Youth in California County Behavioral Health Directors Association of California – All Members Meeting October.
McLean Hospital Division of Alcohol and Drug Abuse
Katherine Neuhausen, MD, MPH Chief Medical Officer
Strategies to Ensure Quality Recovery Housing
David Loveland, Ph.D. Community Care
6th Annual Residential Substance Abuse Treatment Conference
The Overdose Epidemic in RI:
A State Targeted Response to the Opioid Crisis:
What Works? Evidence-Based Practices for Treating Opioid Use Disorder
Medication Assisted Treatment
Impact of Mental Health Policies
Information for Network Providers
Overview of the Addiction Technology Transfer Center Network
National Association of Medicaid Director’s Fall Conference
Primary Prevention in the Time of the Opioid Epidemic
Pain Management and Substance Use Disorders: JCPP Strategic Session
Ten Pearls for Medication Assisted Treatment of Opiate Use Disorders
The Overdose Epidemic in RI:
West Virginia Medicaid Summit
Impact of Policy and Regulatory Responses to the Opioid Epidemic on the Care of People with Serious Illness Hemi Tewarson, Director, Health Division National.
WVAADC Legislative Advocacy Day January 2019
Sustaining Primary Care-Public Health Partnerships for Engagement in Care – The Partnerships for Care Demonstration Project Sue Lin, PhD, MS Director,
Addiction Treatment Program North Canyon Medical Center
South Carolina Department of Alcohol and Other Drug Abuse Services Recovery Services & Work with FAVOR SC.
Preliminary Outcomes of the Texas Access to Recovery Project
Medication Assisted Treatment: Changing the Trajectory of the Opioid Epidemic
Vision Transformative collaboration that fosters resilient self-sustaining Recovery Communities. Mission To develop and sustain measurable solutions that.
A Training For Multidisciplinary Addiction Professionals
Alcohol, Other Drugs, and Health: Current Evidence
Opioid Use Disorders: Impact on HIV
No conflicts of interest
Medically assisted treatment
Medication Assisted Treatment of Opioid Use Disorder
Can be personalized to individual group needs.
Presentation transcript:

Impacting the Opioid Epidemic: Care Delivery Innovations from the Behavioral Health Community Nick Szubiak, MSW, LCSW Director, Clinical Excellence in Addictions National Council for Behavioral Health

Care Delivery Innovations Engagement Collaborative Care Evidenced Based Care Recovery Supports

Collaborative Care Primary Care is a golden opportunity to identify, engage, and treat MAT SBIRT ED initiates to engage overdose survivors to treatment CCBHCs = Certified Community Behavioral Health Clinics CBHOs = Community Behavioral Health Organizations can provide ongoing care management and evidenced based psychosocial interventions Reimbursement = improved outcomes, proactive care, workforce support Collaborative Care for Opioid and Alcohol Use Disorders in Primary Care At 6 months, the proportion of participants who received any OAUD treatment was higher in the CC group compared with usual care 39.0% vs 16.8% A higher proportion of CC participants reported abstinence from opioids or alcohol at 6 months 32.8% vs 22.3% (https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2652574?resultClick=1) Katherine E. Watkins, MD, MSHS1; Allison J. Ober, PhD1; Karen Lamp, MD2; et al

Medication Assisted Treatment MAT is the gold standard for opioid use disorder (OUD) treatment: Reduces drug use Reduces risk of overdose Prevents injection behaviors Reduces criminal behavior 20.2 Million People Have SUD Only a fraction of those that get treatment get MAT 300,000-400,000 people on methadone in a given year 40,000 on buprenorphine 5-10,000 on Naltrexone Only 10% of the prospective MAT patients for (OUD) are receiving it

Why? Perceptions: The perceptions of MAT and its value among patients, practitioners, and institutions – Bias and Discrimination Providers: The availability of qualified practitioners and their capacity to meet patient demand for MAT Payment: The availability and limits of insurance coverage for MAT Coverage for ALL of the MAT medications approved by the Food and Drug Administration. Prior authorization requirements “fail first” policies

Recovery Supports – Part of the Healthcare Continuum Recovery Housing Recovery Education Programs Recovery Employment Peer Coaching Essential Ingredients for Sustained Recovery: Safe and affordable place to live Steady employment and job readiness Education and vocational skills Life and recovery skills Health and wellness Recovery support networks Sense of belonging and purpose Community and civic engagement

Peer Recovery Support Services Services to help individuals and families initiate, stabilize, and sustain recovery Provided by individuals with “lived experience” of addiction and recovery  Non-professional and non-clinical Distinct from case management and treatment Distinct from mutual aid support, such as 12-step groups Provide links to professional treatment, health and social services, and support resources in communities

The Cascade Linkage to care among those diagnosed Medication initiation among those entering care Retention for at least six months among those initiating medication Continuous abstinence among those retained Diagnosis among those affected http://healthaffairs.org/blog/2017/03/13/to-battle-the-opioid-overdose-epidemic-deploy-the-cascade-of-care-model

90-90-90

Opioid Use Disorder is… -not a moral or spiritual failing -not lack of will or responsibility -not a character defect -not an addictive personality type -does not have personality components such as denial, rationalization, evasion, defensiveness, manipulation, and resistance or any abnormally robust defense mechanisms Is Primary Disease - meaning that it’s not the result of other causes such as emotional or psychiatric problems Is Chronic Disease - like cardiovascular disease or diabetes it must be treated, managed and monitored over a life‐time.   The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13–20. Available at:www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2851054&tool=pmcentrez&rendertype=abstract